Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01694771 · ClinicalTrials.gov registry record · Phase 3
Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®
A Phase 3 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,134
- Enrollment target
NCT01694771: Completed Phase 3 study, sponsored by Boehringer Ingelheim.
NCT01694771 is a Phase 3 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,134 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01694771, a Phase 3 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,134 participants
- Enrollment target
Study Summary
The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler® as Spiriva Handihaler®), compared to tiotropium (Spiriva Handihaler®) monotherapy on lung function in patients with COPD.
Primary Outcome
FEV1 (Forced expiratory volume in 1 second) AUC0-3h (area under the curve) response at 12 weeks; defined as change from baseline to Week 12
Interventions
- DRUG Tiotropium
- DRUG Olodaterol
- DRUG Placebo matching Olodaterol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,134 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-08 |
| Phase | Phase 3 |
What the finished NCT01694771 record still lists
NCT01694771 is an interventional study that assigns participants to a tested intervention. Its 1,134 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (47% higher).
The record links to 0 conditions, and to 3 interventions - of which Tiotropium is the first listed.
NCT01694771 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01694771 about?
NCT01694771 is a clinical study titled "Co-administration of Olodaterol Respimat® and Tiotropium Handihaler®". The overall objective of this study is to assess efficacy and safety of 12 weeks, once daily, orally inhaled co-administration of olodaterol 5 µg (delivered by the Respimat® Inhaler) and tiotropium (delivered by the Handihaler® as Spiriva Handihaler®), compared to tiotropium (Spiriva Handihaler®) mo...
What is the current status of trial NCT01694771?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,134 participants. The study started on 2012-09. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01694771?
The interventions under investigation include: Tiotropium (DRUG), Olodaterol (DRUG), Placebo matching Olodaterol (DRUG).
Who is sponsoring clinical trial NCT01694771?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01694771's enrollment target sits among peer trials
1,134 244th of 2000 higher than 1,757 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06445062 · 1,130 participants · Phase 1
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- NCT05894967 · 1,140 participants · NA
Moderators and Mediators of Perceptual Learning
- NCT06532487 · 1,140 participants · NA
Addressing Durable Health Disparities Through Critical Time Legal Interventions in Medically Underserved Latinx and Migrant Communities
- NCT06746129 · 1,126 participants · Phase 3
Cleavage-stage Versus Blastocyst-stage Embryo Transfer in IVF Patients With Few Embryos
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia